keyword
MENU ▼
Read by QxMD icon Read
search

Kpc klebsiella

keyword
https://www.readbyqxmd.com/read/29238932/risk-factors-and-clinical-outcomes-of-hypervirulent-klebsiella-pneumoniae-induced-bloodstream-infections
#1
Jiayang Li, Jianan Ren, Weiping Wang, Gefei Wang, Guosheng Gu, Xiuwen Wu, Ying Wang, Mei Huang, Jieshou Li
The prevalence of hypervirulent Klebsiella pneumoniae (hvKP) is high in China, but clinical characteristics and outcomes of hvKP induced bloodstream infections (BSIs) are not clear. The purpose of the present study was to determine the risk factors and clinical outcomes of hvKP-BSIs in populations admitted in a teaching hospital of Nanjing, China. The genetic characteristics and antibiotic resistance patterns of the hvKP strains were further analyzed. A retrospective study was conducted in 143 patients with K...
December 14, 2017: European Journal of Clinical Microbiology & Infectious Diseases
https://www.readbyqxmd.com/read/29236574/genetic-diversity-of-kpc-producing-escherichia-coli-klebsiella-oxytoca-serratia-marcescens-and-citrobacter-freundii-isolates-from-argentina
#2
Denise De Belder, Celeste Lucero, Melina Rapoport, Adriana Rosato, Diego Faccone, Alejandro Petroni, Fernando Pasteran, Ezequiel Albornoz, Alejandra Corso, Sonia A Gomez
The predominance of Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae was caused by the spread of ST258 clone. In Latin America, KPC was reported in 2006, with the isolation of genetically unrelated K. pneumoniae in Colombia. Since then, the expansion of blaKPC in either K. pneumoniae ST258 or other Enterobacteriaceae (ETB) species was increasingly reported. In this study, we characterized 89 KPC-producing Escherichia coli, Klebsiella oxytoca, Serratia marcescens, and Citrobacter freundii that were received between 2010 and 2014...
December 13, 2017: Microbial Drug Resistance: MDR: Mechanisms, Epidemiology, and Disease
https://www.readbyqxmd.com/read/29232103/game-changers-new-%C3%AE-lactamase-inhibitor-combinations-targeting-antibiotic-resistance-in-gram-negative-bacteria
#3
Karen Bush
Recent regulatory approvals for the β-lactam inhibitor combinations of ceftazidime-avibactam and meropenem-vaborbactam have provided two novel therapeutic options for the treatment of multidrug-resistant infections caused by Gram-negative bacteria. Most importantly, these combination agents have satisfied an important medical need related to antibiotic-resistant Klebsiella pneumoniae that produce serine carbapenemases, especially the Klebsiella pneumoniae carbapenemase (KPC) enzymes. Both combinations contain non-β-lactam β-lactamase inhibitors of novel chemical classes not previously developed as antibacterial agents, the diazabicyclooctanes and cyclic boronic acid derivatives...
December 12, 2017: ACS Infectious Diseases
https://www.readbyqxmd.com/read/29230684/imipenem-relebactam-and-meropenem-vaborbactam-two-novel-carbapenem-%C3%AE-lactamase-inhibitor-combinations
#4
REVIEW
George G Zhanel, Courtney K Lawrence, Heather Adam, Frank Schweizer, Sheryl Zelenitsky, Michael Zhanel, Philippe R S Lagacé-Wiens, Andrew Walkty, Andrew Denisuik, Alyssa Golden, Alfred S Gin, Daryl J Hoban, Joseph P Lynch, James A Karlowsky
Relebactam (formerly known as MK-7655) is a non-β-lactam, bicyclic diazabicyclooctane, β-lactamase inhibitor that is structurally related to avibactam, differing by the addition of a piperidine ring to the 2-position carbonyl group. Vaborbactam (formerly known as RPX7009) is a non-β-lactam, cyclic, boronic acid-based, β-lactamase inhibitor. The structure of vaborbactam is unlike any other currently marketed β-lactamase inhibitor. Both inhibitors display activity against Ambler class A [including extended-spectrum β-lactamases (ESBLs), Klebsiella pneumoniae carbapenemases (KPCs)] and class C β-lactamases (AmpC)...
December 12, 2017: Drugs
https://www.readbyqxmd.com/read/29228202/activity-of-ceftazidime-avibactam-against-problem-enterobacteriaceae-and-pseudomonas-aeruginosa-in-the-uk-2015-16
#5
David M Livermore, Danièle Meunier, Katie L Hopkins, Michel Doumith, Robert Hill, Rachel Pike, Peter Staves, Neil Woodford
Background: Ceftazidime/avibactam combines an established oxyimino-cephalosporin with the first diazabicyclooctane β-lactamase inhibitor to enter clinical use. We reviewed its activity against Gram-negative isolates, predominantly from the UK, referred for resistance investigation in the first year of routine testing, beginning in July 2015. Methods: Isolates were as received from referring laboratories; there is a bias to submit those with suspected carbapenem resistance...
December 8, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/29216954/-advances-in-risk-factors-of-klebsiella-pneumoniae-carbapenemases-producing-klebsiella-pneumoniae-infection-or-colonization-and-its-treatment-strategies
#6
Liang Wu, Jiawei Ying, Zhenhong Jiang, Shu Lei, Jiannong Wu, Dandan Feng, Lingcong Wang
Klebsiella pneumoniae carbapenemases-producing Klebsiella pneumoniae (KPC-Kp) has caused a global public health crisis, and the severity of its infection is associated with high mortality in hospitalized patients. Therefore, the KPC-Kp prevention methods and the corresponding treatment strategy exploration are imminent. The risk factors and the treatment progress of KPC-Kp colonization or infection are reviewed in this paper to explore corresponding preventive measures and treatment strategies for clinical prevention and treatment...
December 2017: Zhonghua Wei Zhong Bing Ji Jiu Yi Xue
https://www.readbyqxmd.com/read/29206750/ceftazidime-avibactam-antimicrobial-activity-and-spectrum-when-tested-against-gram-negative-organisms-from-pediatric-patients-results-from-the-inform-surveillance-program-united-states-2011-2015
#7
Helio S Sader, Michael D Huband, Leonard R Duncan, Robert K Flamm
BACKGROUND: Ceftazidime-avibactam was approved by the US Food and Drug Administration in 2015 to treat complicated intra-abdominal and urinary tract infections in adults, and is under clinical development for treating pediatric patients. METHODS: Among 53,381 gram-negative organisms (1 per patient) collected in 2011-2015, 8,461 (15.9%) were from pediatric (≤17 years-old [yo]) patients. The isolates were collected from 82 US medical centers and susceptibility tested against ceftazidime-avibactam (avibactam at fixed 4 µg/mL) and comparators by reference broth microdilution methods...
December 4, 2017: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/29203494/polymyxin-b-and-zti-01-fosfomycin-for-injection-against-kpc-producing-klebsiella-pneumoniae-evaluation-of-activity-and-emergence-of-resistance
#8
John K Diep, Rajnikant Sharma, Evelyn J Ellis-Grosse, Cely S Abboud, Gauri G Rao
ZTI-01 (fosfomycin for injection) is a broad spectrum antibiotic with a novel mechanism of action and is currently under development in the USA for treatment of complicated urinary tract infections. Globally, fosfomycin and polymyxin B are increasingly being used to treat multi-drug resistant Gram-negative infections. The objectives were to evaluate the pharmacodynamic activity of polymyxin B and fosfomycin alone and in combination against KPC-producing K. pneumoniae and to assess the rate and extent of emergence of resistance to different antibiotic regimens...
December 4, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/29198372/klebsiella-pneumoniae-co-producing-kpc-and-rmtg-finally-targeting-switzerland
#9
Stefano Mancini, Laurent Poirel, Myriam Corthesy, Gilbert Greub, Patrice Nordmann
A carbapenem- and pan-aminoglycoside-resistant Klebsiella pneumoniae strain was isolated from a Brazilian patient hospitalized in a Swiss hospital. The clinical isolate carried genes encoding the KPC-2 carbapenemase and the RmtG 16S rRNA methyltransferase. This is the first report of a carbapenem-resistant K. pneumoniae producing RmtG in Europe.
November 6, 2017: Diagnostic Microbiology and Infectious Disease
https://www.readbyqxmd.com/read/29186402/in-vitro-and-in-vivo-activity-of-single-and-dual-antimicrobial-agents-against-kpc-producing-klebsiella-pneumoniae
#10
Sarath Nath, Farzad Moussavi, Daniel Abraham, David Landman, John Quale
Objectives: Options for treatment of infections due to KPC-producing Klebsiella pneumoniae are limited and combination therapy is often recommended. In this report, the in vitro and in vivo activity of potential therapeutic agents and combinations was assessed against four KPC-producing K. pneumoniae isolates. Methods: Using clinically relevant concentrations, time-kill experiments and the Galleria mellonella model of infection were used to examine the activity of polymyxin B, ceftazidime/avibactam, meropenem, rifampicin and amikacin alone and in combination...
November 23, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/29176971/occurrence-of-extended-spectrum-%C3%AE-lactamases-kpc-type-and-mcr-1-2-producing-enterobacteriaceae-from-wells-river-water-and-wastewater-treatment-plants-in-oltrep%C3%A3-pavese-area-northern-italy
#11
Mariasofia Caltagirone, Elisabetta Nucleo, Melissa Spalla, Francesca Zara, Federica Novazzi, Vittoria M Marchetti, Aurora Piazza, Ibrahim Bitar, Marica De Cicco, Stefania Paolucci, Giorgio Pilla, Roberta Migliavacca, Laura Pagani
To evaluate the water compartment antibiotic-resistance contamination rates, 11 wells, five streams, and four treatment plants located in the Oltrepò Pavese area were screened for the presence of third generation cephalosporins resistant Gram-negative bacteria. Enterobacteriaceae were also characterized for the Extended-Spectrum-β-Lactamases (ESBLs), carbapenemases, and mcr-1 genes presence. From December 2014 to November 2015, 246 water samples were filtered, plated on Plate Count Agar, MacConkey Agar, and MacConkey Agar with cefotaxime...
2017: Frontiers in Microbiology
https://www.readbyqxmd.com/read/29169659/acquisition-of-the-mcr-1-gene-by-a-high-risk-clone-of-kpc-2-producing-klebsiella-pneumoniae-st437-cc258-brazil
#12
Tanise Vendruscolo Dalmolin, Andreza Francisco Martins, Alexandre Prehn Zavascki, Daiana de Lima-Morales, Afonso Luís Barth
We identified one clinical isolate of K. pneumoniae harboring the mcr 1 (plasmid of IncX4 family) and blaKPC-2 (plasmid of IncFIB family) genes in southern Brazil. These findings highlight that K. pneumoniae isolates carrying both mcr-1 and blaKPC-2 may emergence as a serious threat to antimicrobial therapy.
October 5, 2017: Diagnostic Microbiology and Infectious Disease
https://www.readbyqxmd.com/read/29160518/evaluation-of-carbapenem-resistant-enterobacteriaceae-in-a-tertiary-level-reference-hospital-in-rio-grande-do-sul-brazil
#13
Vinícius Victor Lorenzoni, Danielly da Costa Silva, Roberta Filipini Rampelotto, Patrícia Chaves Brites, Bárbara Villa, Rosmari Hörner
INTRODUCTION: The rapid global spread of carbapenem-resistant Enterobacteriaceae (CRE) is a threat to the health system. METHODS: We evaluated the antimicrobial susceptibility profiles of 70 CRE isolated in a tertiary hospital in Brazil between August and December 2015, and determined their resistance mechanisms. RESULTS: The most prevalent microorganism was Klebsiella pneumoniae (95.7%); it showed high-level resistance to carbapenems (>98%), with sensitivity to colistin (91...
September 2017: Revista da Sociedade Brasileira de Medicina Tropical
https://www.readbyqxmd.com/read/29150371/emergence-of-polymyxin-b-resistance-in-a-polymyxin-b-susceptible-kpc-producing-klebsiella-pneumoniae-causing-bloodstream-infection-in-a-neutropenic-patient-during-polymyxin-b-therapy
#14
Alexandre P Zavascki, Raquel Girardello, Cibele M Magagnin, Laura C Antochevis, Rafael A Maciel, Jussara K Palmeiro, Ana C Gales
The emergence of resistance to polymyxins in KPC-producing Klebsiella pneumoniae isolates has been a major clinical problem. This study evaluated the molecular mechanisms associated with polymyxin B (PMB) resistance that emerged in a previously PMB-susceptible KPC-2-producing K. pneumoniae during PMB therapy for a bloodstream infection in a neutropenic patient. The first isolate (PMB-susceptible) was obtained while the patient was receiving meropenem and other isolates were recovered from 2 sets of blood cultures in different dates while the patient was receiving PMB therapy (4 of 6 blood cultures bottles yielded isolates with full PMB resistance)...
October 19, 2017: Diagnostic Microbiology and Infectious Disease
https://www.readbyqxmd.com/read/29133570/activity-of-simulated-human-dosage-regimens-of-meropenem-and-vaborbactam-against-carbapenem-resistant-enterobacteriaceae-in-an-in-vitro-hollow-fiber-model
#15
Mojgan Sabet, Ziad Tarazi, Debora Rubio-Aparicio, Thomas G Nolan, Jonathan Parkinson, Olga Lomovskaya, Michael N Dudley, David C Griffith
The objective of these studies was to evaluate the exposures of meropenem and vaborbactam that would produce antibacterial activity and prevent resistance development in carbapenem-resistant, Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains when tested at an inocula of 10(8) CFU/mL. Thirteen K. pneumoniae isolates, three Enterobacter cloacae isolates, and one Escherichia coli isolate were examined in an in vitro hollow fiber model over 32 hours. Simulated dosage regimens of meropenem 1-2 g with vaborbactam 1-2 g, meropenem administered every 8 hours by 3 hour infusion based on Phase 1 or Phase 3 patient pharmacokinetic data were studied in the model...
November 13, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/29126236/identification-and-genomic-characterization-of-a-kpc-2-ndm-1-and-ndm-5-producing-klebsiella-michiganensis-isolate
#16
Beiwen Zheng, Hao Xu, Xiao Yu, Tao Lv, Xiawei Jiang, Hong Cheng, Jing Zhang, Yunbo Chen, Chen Huang, Yonghong Xiao
No abstract text is available yet for this article.
November 8, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/29126110/risks-of-infection-and-mortality-among-patients-colonized-with-kpc-producing-klebsiella-pneumoniae-validation-of-scores-and-proposal-for-management
#17
Angela Cano, Belén Gutiérrez-Gutiérrez, Isabel Machuca, Irene Gracia-Ahufinger, Elena Pérez-Nadales, Manuel Causse, Juan José Castón, Julia Guzman-Puche, Julian Torre-Giménez, Lara Kindelán, Luis Martínez-Martinez, Jesús Rodriguez-Baño, Julian Torre-Cisneros
Background: The management and indication of empirical treatment in Klebsiella pneumoniae-carbapenemase producing K. pneumoniae (KPC-Kp) colonized patients should be improved. Methods: A prospective cohort of 94 patients colonized by KPC-Kp was followed for 90 days to validate: (i) the Giannella risk score (GRS) to predict the development of any type of KPC-Kp infection and (ii) the INCREMENT-CPE score (ICS) to predict 30-day mortality in patients with infection...
November 8, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29111353/clinical-factors-predicting-persistent-carriage-of-kpc-producing-carbapenem-resistant-enterobacteriaceae-among-patients-with-known-carriage
#18
Yong Kyun Kim, Sae Am Song, Jeong Nyeo Lee, Minkyung Oh, Kyeong Min Jo, Hyo-Jung Kim, Jae Ha Lee, Jin-Han Park, Hang-Jea Jang, Hyeon-Kuk Kim, Sungmin Kiem
BACKGROUND: Information on the natural duration of carbapenem-resistant Enterobacteriaceae (CRE) carriage and factors associated with persistence of carriage is limited. AIM: To evaluate the clinical variables associated with persistent carriage of Klebsiella pneumoniae carbapenemase (KPC)-producing CRE. METHODS: We retrospectively reviewed data for patients admitted between June 2015 and December 2016 who were identified as KPC-producing CRE carriers by either rectal swabs or clinical cultures...
October 27, 2017: Journal of Hospital Infection
https://www.readbyqxmd.com/read/29101083/draft-genome-sequence-of-a-tigecycline-resistant-kpc-2-producing-klebsiella-pneumoniae-st15-clinical-isolate-from-china
#19
Juan Xu, Meng Gao, Yan Hong, Fang He
OBJECTIVES: Carbapenem-resistant Klebsiella pneumoniae (CRKP) infections have emerged worldwide as a serious challenge to public health. Tigecycline is regarded as one of the last-resort antimicrobials for CRKP infections. Here we report the draft genome sequence of a clinical tigecycline-resistant KPC-2-producing K. pneumoniae isolate (TRKP1). METHODS: Whole-genome sequencing of strain TRKP1 was performed using an Illumina Hiseq™ X Ten system. The generated reads were assembled using CLC Genomics Workbench...
October 31, 2017: Journal of Global Antimicrobial Resistance
https://www.readbyqxmd.com/read/29097338/expansion-of-kpc-producing-klebsiella-pneumoniae-with-various-mgrb-mutations-giving-rise-to-colistin-resistance-the-role-of-isl3-on-plasmids
#20
Cesira Giordano, Simona Barnini, Constantinos Tsioutis, Monika A Chlebowicz, Effie V Scoulica, Achilleas Gikas, John W Rossen, Alexander W Friedrich, Erik Bathoorn
BACKGROUND: mcr-1 has been reported as first plasmid gene to confer colistin-resistance. In KPC-producing Klebsiella pneumoniae (KPC-KP) isolates, however, colistin resistance is rapidly emerging through other mechanisms. This is frequently the result of disruption of mgrB gene by insertion sequences, for instance ISL3. The aim of this study is to investigate the expansion of mgrB-mutated KPC-KP. In addition, we identify localization and targets of ISL3 sequences within the core and accessory genome of common KPC-KP lineages...
October 27, 2017: International Journal of Antimicrobial Agents
keyword
keyword
117151
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"